Myotonic Dystrophy Type 1
18
6
8
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 18 trials
100.0%
+13.4% vs benchmark
6%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (18)
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2
Virtual Reality-training in Theory of Mind in the Childhood Form of Myotonic Dystrophy Type 1
Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
Fall Frequency and Factors Affecting Dynamic Balance in Patients With Myotonic Dystrophy Type 1
The Spanish National Registry for Myotonic Dystrophy Type 1
Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Pelvic Floor Muscle Training for Women with Myotonic Dystrophy
Wheelchair Skills Training for People with ARSACS and DM1
A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study)
Multicenter Observational Study of Myotonic Dystrophy Type 1
Observational Prolonged Trial in Myotonic Dystrophy Type 1
Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy